THE ROLE OF PSMA PET/CT IN IMAGING PROSTATE CANCER
INTRODUCTION: Accurate evaluation of the extent of disease in patients with prostate cancer is of great importance in guiding suitable treatment at all disease stages. Conventional imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), which rely on morphological criteria, are limited in assessing the real extent of prostate cancer. In recent years, molecular imaging via PET/CT using small molecules targeting the prostate-specific membrane antigen (PSMA) protein on prostate cancer cells linked to positron emitting isotopes has emerged as a promising diagnostic tool. PSMA PET/CT, with its high sensitivity and specificity, has revolutionized the field of prostate cancer imaging. The main indications for PSMA PET/CT imaging are staging of high-risk patients and evaluation of biochemical failure. In addition, PSMA-targeting particle-emitting radioligands allow targeted therapy in patients with advanced disease, with promising results.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:160 |
|---|---|
| Enthalten in: |
Harefuah - 160(2021), 7 vom: 01. Juli, Seite 455-461 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Kuten, Jonathan [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 16.07.2021 Date Revised 16.07.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM328090964 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328090964 | ||
| 003 | DE-627 | ||
| 005 | 20231225202219.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328090964 | ||
| 035 | |a (NLM)34263574 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Kuten, Jonathan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a THE ROLE OF PSMA PET/CT IN IMAGING PROSTATE CANCER |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.2021 | ||
| 500 | |a Date Revised 16.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Accurate evaluation of the extent of disease in patients with prostate cancer is of great importance in guiding suitable treatment at all disease stages. Conventional imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), which rely on morphological criteria, are limited in assessing the real extent of prostate cancer. In recent years, molecular imaging via PET/CT using small molecules targeting the prostate-specific membrane antigen (PSMA) protein on prostate cancer cells linked to positron emitting isotopes has emerged as a promising diagnostic tool. PSMA PET/CT, with its high sensitivity and specificity, has revolutionized the field of prostate cancer imaging. The main indications for PSMA PET/CT imaging are staging of high-risk patients and evaluation of biochemical failure. In addition, PSMA-targeting particle-emitting radioligands allow targeted therapy in patients with advanced disease, with promising results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Kesler, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Even-Sapir, Einat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 160(2021), 7 vom: 01. Juli, Seite 455-461 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:160 |g year:2021 |g number:7 |g day:01 |g month:07 |g pages:455-461 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 160 |j 2021 |e 7 |b 01 |c 07 |h 455-461 | ||